Changes in Microbiota and Quality of Life in IBS - Trial NCT05266287
Access comprehensive clinical trial information for NCT05266287 through Pure Global AI's free database. This phase not specified trial is sponsored by National University of Natural Medicine and is currently Not yet recruiting. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
a supplement containing 2'-fucosyllactose (2'-FL)
Interventional
dietary supplement
Sponsor & Location
National University of Natural Medicine
Timeline & Enrollment
N/A
Mar 01, 2022
Dec 31, 2022
Primary Outcome
F. Prausnitzii abundance
Summary
The primary research question to be addressed is: Does a 2'-FL-containing dietary supplement
 impact stool microbiota composition in adults with IBS? The primary measure for determining
 potential impacts of the 2'-FL-containing dietary supplement on stool microbiota composition
 is stool abundance of Faecalibacterium prausnitzii, a commensal intestinal bacteria.
 Additional measures related to determining potential impacts of the 2'-FL-containing dietary
 supplement on gut microbiota composition are stool levels of additional commensal intestinal
 bacteria and measures of intestinal microbial diversity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05266287
Non-Device Trial